 | • レポートコード：MRC2303K103 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界の免疫タンパク質診断検査市場規模が、予測期間中、CAGR 7.7％で増大すると予測されています。本レポートでは、免疫タンパク質診断検査の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品種類別（器具、キット・試薬、その他）分析、技術別（化学発光法、免疫蛍光法、免疫濁度法、免疫タンパク質電気泳動、その他）分析、用途別（感染症、内分泌腺、毒性学、その他）分析、地域別（アメリカ、カナダ、日本、韓国、中国、インド、オーストラリア、ベトナム、マレーシア、インドネシア、フィリピン、タイ、イギリス、フランス、ドイツ、イタリア、スペイン、ロシア、メキシコ、ブラジル、サウジアラビア、イラン、エジプト、オマーン、南アフリカ）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Abbott、Bio-Rad Laboratories Inc.、Calbiotech Inc.、DiaSys Diagnostic Systems GmbH、Diazyme Laboratories Inc.、Enzo Lifesciences Inc.、F. Hoffmann-La Roche Ltd、Randox Laboratories、SERVA Electrophoresis GmbH、Thermofisher Scientific Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の免疫タンパク質診断検査市場規模：製品種類別 - 器具の市場規模 - キット・試薬の市場規模 - その他製品の市場規模 ・世界の免疫タンパク質診断検査市場規模：技術別 - 化学発光法における市場規模 - 免疫蛍光法における市場規模 - 免疫濁度法における市場規模 - 免疫タンパク質電気泳動における市場規模 - その他技術における市場規模 ・世界の免疫タンパク質診断検査市場規模：用途別 - 感染症における市場規模 - 内分泌腺における市場規模 - 毒性学における市場規模 - その他用途における市場規模 ・世界の免疫タンパク質診断検査市場規模：地域別 - 北米の免疫タンパク質診断検査市場規模 アメリカの免疫タンパク質診断検査市場規模 カナダの免疫タンパク質診断検査市場規模 メキシコの免疫タンパク質診断検査市場規模 … - ヨーロッパの免疫タンパク質診断検査市場規模 ドイツの免疫タンパク質診断検査市場規模 イギリスの免疫タンパク質診断検査市場規模 フランスの免疫タンパク質診断検査市場規模 … - アジア太平洋の免疫タンパク質診断検査市場規模 中国の免疫タンパク質診断検査市場規模 日本の免疫タンパク質診断検査市場規模 インドの免疫タンパク質診断検査市場規模 … - 南米/中東の免疫タンパク質診断検査市場規模 南アフリカの免疫タンパク質診断検査市場規模 ブラジルの免疫タンパク質診断検査市場規模 アルゼンチンの免疫タンパク質診断検査市場規模 … ・競争状況 ・市場機会・将来動向 |
The Immunoprotein Diagnostic Testing Market is expected to register a CAGR of 7.7% over the forecast period.
COVID-19 had a substantial effect on the market’s expansion. Effective individual COVID-19 infection diagnosis was urgently necessary due to increased cases and significant mortality. Using immunoglobulin tests in the COVID-19 condition was effective for better disease diagnosis. Furthermore, the new research studies of immunoglobulin diagnostic tests will help the market to grow over the coming years. For instance, according to the report published by Virology Journal, in February 2022, the study evaluates and compares the six antibody assays and two combination assays for COVID-19 diagnosis. According to the result of the study, people should use highly sensitive assays as frequently as feasible for epidemiological surveillance of COVID-19 infection. Thus, the new research studies over the coming years will impact the market positively and are expected to have stable growth over the post-pandemic era.
The immunoprotein diagnostic testing market will grow due to the growing burden of chronic diseases and technological advancements related to the products. The rising prevalence of chronic diseases like diabetes will significantly impact the immunoprotein diagnostic testing market as the test can differentiate type 1 diabetes and latent autoimmune diabetes in adulthood. For instance, as per the 2022 JDRF, it is estimated about 8.7 million people are living with type 1 diabetes around the world. Similarly, as per the report published by Lancet Diabetes & Endocrinology in October 2022, it is estimated that by 2040, there will be 13.5–17.4 million cases of type 1 diabetes around the world. Thus the increase in the prevalence of chronic issues increases the demand for immunoprotein diagnostic tests, which will drive the market over the forecast period.
Furthermore, the government provides few surveillance programs for antibody tests, which can significantly impact the market. For instance, in August 2021, the United Kingdom Health Security Agency launched an antibody surveillance program across the UK for the general public. It improves understanding of the protection provided by antibodies generated following COVID-19 infection and vaccination. For the evaluation of the antibodies, immunoprotein diagnostic tests need to get conducted to evaluate the antibodies.
Hence, these expensive techniques will impede market growth over the forecast period.
Immunoprotein Diagnostic Testing Market Trends
Endocrine Segment is Expected to Hold a Significant Share in the Market Over the Forecast Period
The endocrine segment is expected to exhibit steady growth in the immunoprotein diagnostic testing market. The growing burden of endocrine diseases, such as diabetes, and the development of products related to immunodiagnostic testing drive the segment’s growth.
According to the Type 1 Diabetes Index, 2022, in the US, type 1 diabetes is growing at 2.9% each year compared with 4.5% for type 2 diabetes. Similarly, as per the US CDC, in 2022, 96 million adults have prediabetes in the US, and 8 in 10 of them are not aware if they have it. More than 37 million people live with diabetes, and 1 in 5 go undiagnosed. Hence the significant rise in the prevalence of diabetes increases the demand for the diagnosis using immunoprotein tests which will have a positive impact on the market.
Furthermore, the technological advancements in immunoprotein testing help the market growth through product approvals and launches. For instance, in May 2022, Labcorp made screening for diabetes easier by launching an at-home collection kit through Labcorp OnDemand that measures hemoglobin A1c (HbA1c) from a small blood sample.
Thus, the above factors will likely drive the segment’s growth during the forecast period.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
The major factors driving the market growth in North America include rising healthcare expenditure and a growing level of consciousness for the products involved in diagnosing autoimmune disorders. North America is expected to be a dominant region, owing to the rising geriatric population and the growing burden of diseases along with the new product developments and launches.
According to the IDF Diabetes Atlas 2021, the age-adjusted comparative diabetes prevalence in the US was 10.7% for 2021 and expected to be 12.1% and 12.9% for 2030 and 2045, respectively. As per the same source, the age-adjusted comparative diabetes prevalence in Canada was 7.7% for 2021 and estimated to be 8.9% and 9.% for 2030 and 2045, respectively. It shows the growing prevalence of chronic diseases like diabetes in the North American region. It increases the demand for diagnosis using immunoprotein tests that may positively impact the market’s growth over the forecast period.
Furthermore, new product approvals and launches in the region with collaborations among the major players in the market will drive market growth. For instance, in May 2022, OmegaQuant launched an HbA1c Test with a sample collection kit that allows for testing at home. This simple, safe, convenient test measures the amount of sugar (glucose) in the blood. Thus, it will positively influence the immunoprotein diagnostic testing market and witness significant growth in North America over the forecast period due to the abovementioned factors.
Immunoprotein Diagnostic Testing Market Competitor Analysis
The immunoprotein diagnostic testing market is slightly fragmented. Key players expected to be dominant in the immunoprotein diagnostic testing market are Thermofisher Scientific Inc., Enzo Lifesciences Inc., Randox Laboratories, Bio-Rad Laboratories Inc., Abbott, SERVA Electrophoresis GmbH, F. Hoffmann-La Roche Ltd, Diazyme Laboratories Inc., DiaSys Diagnostic Systems GmbH, and Calbiotech Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Diseases
4.2.2 Technological Advancements of Products
4.3 Market Restraints
4.3.1 Expenisive Techniques
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Product Type
5.1.1 Instruments
5.1.2 Kits and Reagents
5.1.3 Other Product Types
5.2 By Technology
5.2.1 Chemiluminescence Assay
5.2.2 Immunofluorescence Assay
5.2.3 Immunoturbidity Assay
5.2.4 Immunoprotein Electrophoresis
5.2.5 Other Technologies
5.3 By Application
5.3.1 Infectious Disease
5.3.2 Endocrine
5.3.3 Toxicology
5.3.4 Other Applications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott
6.1.2 Bio-Rad Laboratories Inc.
6.1.3 Calbiotech Inc.
6.1.4 DiaSys Diagnostic Systems GmbH
6.1.5 Diazyme Laboratories Inc.
6.1.6 Enzo Lifesciences Inc.
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 Randox Laboratories
6.1.9 SERVA Electrophoresis GmbH
6.1.10 Thermofisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS